Japanese launch of ActHIB delayed
This article was originally published in Scrip
Manufacturing issues have delayed the Japanese launch of Sanofi Pasteur-Daiichi Sankyo Vaccines' paediatric meningitis vaccine ActHIB. The Haemophilus influenzae type b prophylactic vaccine was approved back in January 2007 and was expected to reach the market this summer. However, batch production to a standard required for the Japanese market has taken longer than expected, the Japanese joint venture said. A December launch following the import of an increased quantity from Sanofi Pasteur in France is now planned, although a final date has not been fixed. Daiichi Sankyo will distribute the product, which is not currently eligible for reimbursement under Japan's national insurance system.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.